Researchers conducted a randomized clinical trial to assess whether 24 weeks of treatment with rotigotine can modify cognitive functions in patients with mild to moderate Alzheimer disease.
Heightened cognitive arousal at bedtime is linked to objective sleep disturbances and indicators of psychological hyperarousal at night and during the day.
Depression and anxiety were significantly associated with sleep difficulties, including trouble falling asleep, early waking, coughing or snoring, feeling too cold or too hot, and having a bad dream.
Although the American Academy of Pediatrics has published thorough guidelines and recommendations for screening for developmental disorders, many clinicians have not incorporated screening into routine well visits.
Evidence lacking for screening for community-dwelling older adults with no signs or symptoms.
Children living in rural areas are more likely to be diagnosed with a developmental disability compared with those living in urban areas.
No increases for depressive, anxiety symptoms seen with screening in rural, suburban, urban primary care clinics.
Rate of decline in memory, global cognition similar for elderly statin users, never users over 6-year period.
Number of hospital days up by more than 50% in AD patients initiating antipsychotic medication.
New analysis of study results suggests highest dose of aducanumab may help slow cognitive decline.
